Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Muckle-Wells Syndrome: randomized withdrawal study
2006-005455-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Muckle-Wells syndrome (MWS) comparing Canakinumab continuation arm with Placebo withdrawal arm (2 arms). Primary endpoint: Proportion of patients with disease flare in withdrawal phase. Started Feb 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
Muckle-Wells syndrome (MWS)
Beyond the preview
Go deeper on 2006-005455-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005455-15.